38,037 11,236,501
Total non current liabilities 11,238,037 11,236,501
Total liabilities 49,886,084 45,334,533
EQUITY:
Shareholders' equity of the Company:
Common stock, $0.001 par value,
250,000,000 shares authorized,
71,333,586 issued and outstanding,
respectively 71,334 71,334
Paid-in-capital 18,118,007 18,042,189
Statutory reserves 13,217,217 13,217,217
Retained earnings 129,631,801 126,370,263
Accumulated other comprehensive
income 18,277,093 18,262,123
Total shareholders' equity of the
Company 179,315,452 175,963,126
Noncontrolling interest 10,161,377 9,812,049
Total equity 189,476,829 185,775,175
Total liabilities and equity $239,362,913 $231,109,708
TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2010 AND 2009 (UNAUDITED)
Three months ended March 31,
2010 2009
CASH FLOWS FROM OPERATING
ACTIVITIES:
Net income $3,603,595 $8,999,799
Adjustments to reconcile net
income to cash
provided by (used in) operating
activities:
Provision for doubtful accounts 202,247 (184,568)
Depreciation 417,469 544,811
Amortization 83,557 97,143
Interest expense
'/>"/>SOURCE Tiens Biotech Group (USA), Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1.
Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results2.
Tiens Biotech Group (USA) Reports First Quarter Results3.
Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results4.
eFuture Signs Contract to Provide Tiens Group with Retail Business Management System5.
Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results6.
Cutting-Edge Vaccine Research to be Showcased at AAPS National Biotechnology Conference7.
Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership8.
BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimers Disease9.
TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)10.
Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results11.
IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.